GET DAILY SIGNALSGuardian Pharmacy Services (GRDN) Shows Margin Strength in Q3 Despite Modest Revenue Dip
Key Takeaways
- Third quarter 2026 revenue reached $371.07 million, down 1.7% from the prior year, as Inflation Reduction Act drug-price reductions offset otherwise solid underlying growth.
- Adjusted EPS came in at $0.33, beating the $0.32 consensus estimate, while revenue topped the roughly $366 million analyst forecast.
- Gross profit increased 14% to $85.2 million, and adjusted EBITDA rose 24% to $33.9 million.
- Net income roughly doubled to about $18.7 million from $9.6 million a year earlier.
- Management lifted full-year 2026 guidance for both revenue and adjusted EBITDA on the back of strong operating momentum.
- Guardian ended the quarter serving roughly 218,000 residents, holding about $120 million in cash and carrying no debt.
Why the Quarter Matters
Guardian Pharmacy Services stands as one of the larger long-term care pharmacy providers in the country, working with assisted living facilities, behavioral health centers, and group homes to supply medications along with technology-enabled services. The third quarter 2026 results stand out because they arrived amid notable reimbursement shifts from IRA drug-pricing changes that have weighed on reported revenue this year. I have been watching closely to see whether cost discipline, purchasing programs, and organic expansion could support profitability even as top-line growth moderated. The company’s ability to widen margins and raise guidance sends a useful signal about the resilience of its operating model in the face of ongoing healthcare policy pressures.
The Quarter’s Reported Figures
Guardian Pharmacy Services posted third quarter 2026 revenue of $371.07 million, a 1.7% decline from $377.43 million in the same period last year. Management noted that, excluding IRA-related drug-price reductions, revenue would have risen in the high single digits, pointing to organic growth. Adjusted EPS of $0.33 cleared the $0.32 consensus mark, and revenue also exceeded analyst expectations. Profitability metrics improved notably. Gross profit advanced 14% to $85.2 million, with the gross margin moving higher sequentially to 23%. Adjusted SG&A expenses totaled $57.4 million, or 15.5% of revenue. Adjusted EBITDA climbed 24% year over year to $33.9 million, for a 9.1% EBITDA margin. Net income rose to roughly $18.7 million from $9.6 million a year earlier, with an effective tax rate of 26%.
Operationally, the number of residents served grew in the high single digits to approximately 218,000, and prescription volumes increased 10% year over year. Following these results, the company raised its full-year 2026 outlook to revenue of $1.44 billion to $1.46 billion (previously $1.43 billion to $1.45 billion) and adjusted EBITDA of $136 million to $138 million (previously $129 million to $131 million).
I also checked this using Tickeron’s AI Screener to see how GRDN stacks up against peers in the healthcare space.
Investor Reaction and Sentiment
Heading into the report, sentiment was generally constructive, with GRDN shares up about 40% year to date and several analysts holding Buy or Overweight ratings. The central question for investors was whether margin expansion and cash generation could continue to offset the IRA-driven revenue pressure. The numbers provided a positive response: profitability accelerated even as reported revenue declined, and management raised full-year guidance for the second straight quarter.
Attention is likely to stay on the balance between reimbursement pressure and organic growth. Although the revenue headline looks soft at first glance, the underlying high-single-digit growth and expanding margins indicate the business is handling the policy shift more effectively than some had anticipated. Investor focus is also shifting to the recent share-structure change, with the final tranche of Class B shares converting to Class A in late September and new lock-up agreements covering roughly 30 million insider-held shares through September 2027.
What Lies Ahead
Looking forward, investors will want to track whether Guardian can maintain its margin trajectory as IRA pricing changes fully work through the business. Management has signaled that revenue comparisons should remain pressured by these headwinds, yet underlying organic growth should hold in the high single digits. Continued progress on purchasing initiatives, plan optimization, and vaccine programs will matter for gross margin performance.
Capital allocation is another area worth monitoring. Guardian closed the quarter with approximately $120 million in cash and no debt, providing room for acquisitions and greenfield pharmacy openings. Guidance continues to exclude any future acquisitions, so completed deals could represent additional upside. Recent purchases such as Wellness Concepts, Nautilus Pharmacy, and Van’s Institutional Pharmacy illustrate an active strategy in a fragmented market.
Finally, tracking the reimbursement environment, including value-based arrangements with payors, along with the effects of the share-class conversion and lock-up agreements on liquidity and insider alignment, will help shape the outlook for growth and profitability in coming quarters.
Integrating Tickeron Tools Into My Process
In my own research, I frequently turn to Tickeron’s AI Screener to quickly filter healthcare names by fundamentals, technical patterns, and AI-driven signals. It helps surface comparable ideas and confirm how a stock like GRDN fits within its sector without spending hours on manual screens. The tool’s customizable filters make it straightforward to spot trends or breakout candidates that align with the themes I am already following in earnings reports.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GRDN sees its Stochastic Oscillator ascending out of oversold territory
On October 29, 2026, the Stochastic Oscillator for GRDN moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 18 instances where the indicator left the oversold zone. In 17 of the 18 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on GRDN as a result. In 35 of 39 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for GRDN just turned positive on October 29, 2026. Looking at past instances where GRDN's MACD turned positive, the stock continued to rise in 13 of 14 cases over the following month. The odds of a continued upward trend are 90%.
GRDN moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where GRDN advanced for three days, in 119 of 140 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The 10-day moving average for GRDN crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 5 of 8 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GRDN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
GRDN broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GRDN entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 31 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. GRDN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 69 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.855) is normal, around the industry mean (204.059). P/E Ratio (40.086) is within average values for comparable stocks, (18.581). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.091) among similar stocks. P/S Ratio (2.023) is also within normal values, averaging (2.688).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GRDN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement